



10 July 2026

Medicine Supply Alert Notice

Latanoprost 50micrograms/ml / Timolol 5mg/ml (Fixapost®) preservative free eye drops, 0.2ml unit dose

Priority: Level 2*
Valid until: January 2027

Issue

1. Latanoprost 50micrograms/ml / Timolol [0.5%] 5mg/ml (Fixapost®) preservative free eye drops, 0.2ml unit dose, are out of stock until January 2027.
2. Latanoprost 50micrograms/ml / Timolol [0.5%] 5mg/ml (Vizilatan Duo®) preservative free eye drops remain available but cannot support increased demand.
3. Latanoprost 50micrograms/ml / Timolol 5mg/ml eye drops (containing preservatives) remain available.
4. Timolol (Eysano®) 5mg/ml [0.5%] preservative free eye drops remain available but cannot support increased demand.
5. Timolol (Eysano®) 2.5mg/ml [0.25%] preservative free eye drops are out of stock until September 2026.
6. **Latanoprost (Monopost®) 50micrograms/ml preservative free eye drops, 0.2ml unit dose, remain available and can support increased demand.**
7. **Timolol (Tiopex®) 1mg/g [0.1%] preservative free eye gel, 0.4g unit dose, remains available and can support increased demand.**

Advice and Actions

8. Prescribers should not initiate new patients on Fixapost® preservative free eye drops until the supply issue has resolved.
9. Where existing patients have insufficient supply to last until the re-supply date(s), prescribers should:
 - establish reason for use of a preservative free product and consider if a preservative containing product equivalent to Fixapost® could be trialled in some patients (see additional information section);
 - if a preservative free product is deemed necessary, consider appropriateness of prescribing latanoprost (Monopost®) preservative free eye drops with a lower strength (0.1%) preservative free timolol product (Tiopex® eye gel), ensuring that patients are counselled on how to administer Tiopex®, as well as on sequential administration of the components (see additional information section);
 - take into account treatment history including hypersensitivity or adverse reactions to topical eye preparations; and

- where patients are on extended follow-up, or are being seen through diagnostic pathways, notify the glaucoma centre responsible for the patient's care to ensure appropriate monitoring is in place and intraocular pressure control is maintained following the change in treatment.

10. Where the above action is not appropriate, seek specialist advice on treatment options.

Additional Information

Clinical Information

11. Fixapost® contains the prostaglandin analogue, latanoprost (50micrograms/ml) and beta blocker, timolol (5mg/ml [0.5%]). It is licensed for use in adults for the reduction of intraocular pressure in those with open angle glaucoma and ocular hypertension who are insufficiently responsive to either topical beta-blockers or prostaglandin analogues. It is presented as single dose containers and administered once daily.
12. Of the components of Fixapost® available as preservative free products and able to support the gap in market, Monopost® provides the same strength of latanoprost (50micrograms/ml) but TiopeX® is a lower strength timolol product (0.1%), however, specialists consider that concentration can be changed during a shortage to ensure treatment is not omitted, and also ensuring least disruption to eye services.
13. After administering latanoprost, allow at least 15 minutes before administering TiopeX®. The eye gel should be the last medication instilled.
14. **Preservative-free products may be recommended if a patient is using eye drops more than 6 times a day, wears soft or hybrid contact lenses, has a chronic eye disease, or is on multiple preserved topical medication, has a preservative allergy, has ocular surface disease or inflammation, or if there is evidence of toxicity.**

Links to further information

- [SmPC Fixapost® Preservative Free Eye Drops](#)
- [SmPC MONOPOST® \(latanoprost\) 50 mcg/ml eye drops, solution in single-dose container](#)
- [SmPC TIOPEX® \(timolol\) 1 mg/g, eye gel in single-dose container](#)
- [BNF Latanoprost with timolol](#)
- [BNF Treatment summary - Glaucoma and ocular hypertension](#)
- [CKS Glaucoma](#)

Specialist Pharmacy Service (SPS) website

15. The UK Department of Health and Social Care (DHSC) in conjunction with the Specialist Pharmacy Service (SPS) have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.

16. Prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland are encouraged to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

Enquiries

17. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to PharmacyTeam@gov.scot (primary care) or NSS.NHSSMedicineShortages@nhs.scot (secondary care).